Advertisement
Advertisement
DNLI
Denali Therapeutics Inc. Common Stock
19.72
USDSponsored
-0.41
-2.04%
Sep 18, 15:59 UTC -4
Closed
After-Market
19.68
-0.04
-0.20%
DNLI Earnings Reports
Positive Surprise Ratio
DNLI beat 17 of 35 last estimates.
49%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$10.87M
/-$0.54
Implied change from Q2 26 (Revenue/ EPS)
+201.60%
/-20.59%
Implied change from Q3 25 (Revenue/ EPS)
--
/-27.03%
Denali Therapeutics Inc. Common Stock earnings per share and revenue
On Aug 06, 2026, DNLI reported earnings of -0.68 USD per share (EPS) for Q2 26, missing the estimate of -0.66 USD, resulting in a -1.51% surprise. Revenue reached 3.60 million, compared to an expected 14.91 million, with a -75.82% difference. The market reacted with a +0.40% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 10 analysts forecast an EPS of -0.54 USD, with revenue projected to reach 10.87 million USD, implying an decrease of -20.59% EPS, and increase of 201.60% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Therapeutics Inc. Common Stock
Report Date
Sep 08, 2026 For Q3 26
Estimate
-$0.43
Actual
-$0.47
Surprise
-7.16%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were Denali Therapeutics Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Denali Therapeutics Inc. Common Stock reported EPS of -$0.68, missing estimates by -1.51%, and revenue of $3.60M, -75.82% below expectations.
How did the market react to Denali Therapeutics Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 0.4%, changed from $24.73 before the earnings release to $24.83 the day after.
When is Denali Therapeutics Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Denali Therapeutics Inc. Common Stock's next earnings report?
Based on 10
analysts, Denali Therapeutics Inc. Common Stock is expected to report EPS of -$0.54 and revenue of $10.87M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.